IP Library Granted Patent US 8,460,933
Granted Patent B2
US 8,460,933 · App. 12/084,728 · Granted Jun 11, 2013

Expression system incorporating a capsid promoter sequence as an enhancer

Inventors: Edward Peter Rybicki (Cape Town, ZA); Fiona Lesley Tanzer (Cape Town, ZA)
Assignees: South African Medical Research Council; University of Cape Town
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,460,933
App. No.
12/084,728
Granted
Jun 11, 2013
Kind
B2
Abstract

The invention provides a method for enhancing expression of a transgene in a host cell, which includes the steps of inserting a capsid promoter element (Pcap), or a sequence comprising the reverse complement of the capsid promoter element (PcapR), into a mammalian expression cassette upstream (5′) of a cytomegalovirus immediate/early enhancer/promoter region (Pcmv); inserting the transgene into the expression cassette downstream (3′) of the cytomegalovirus immediate/early enhancer/promoter region; inserting a vector containing the expression cassette into the host organism; and causing expression of the transgene. The capsid promoter element (Pcap) is typically from a circovirus, parvovirus or anellovirus. The transgene is typically expressed at a higher level than when expressed by a vector containing the expression cassette without the transcriptional control element. An expression cassette, vector, DNA vaccine, pharmaceutical composition and method of treatment are also claimed.

Claims (17)

1. A method for enhancing expression of a transgene from a cytomegalovirus immediate/early promoter (Pcmv) in a host cell comprising the steps of:

(a) inserting a porcine circovirus type 1 capsid gene promoter (Pcap) or a Pcap reverse complement sequence (PcapR) as shown in SEQ ID NOs: 1 or 2 into a mammalian expression cassette upstream (5′) of the Pcmv promoter element;

(b) inserting the transgene into the mammalian expression cassette downstream (3′) of the Pcmv element;

(c) inserting the expression cassette into the host organism; and

(d) causing expression of the transgene.

2. The method of claim 1 , wherein a cytomegalovirus intron is inserted downstream (3′) of the Pcmv and a bovine growth hormone polyadenylation site (bgh polyA) is inserted downstream (3′) of the transgene.

3. The method of claim 1 , wherein the Pcap or PcapR is inserted immediately upstream (5′) of the Pcmv element.

4. The method of claim 1 , wherein the Pcap or PcapR is inserted up to 1100 base pairs upstream (5′) of the Pcmv element.

5. The method of claim 1 , wherein the host cell is a mammalian cell line for in vitro transgene expression or a cell of a mammalian host organism for in vivo transgene expression.

6. A mammalian expression cassette comprising:

(a) a cytomegalovirus immediate/early promoter (Pcmv) element; and

(b) a sequence that is the Pcap or PcapR located upstream (5′) of the Pcmv element, wherein the Pcap or PcapR comprises SEQ ID NO: 1 or SEQ ID NO: 2;

wherein the Pcap or PcapR enhances the Pcmv promoter activity.

7. The mammalian expression cassette of claim 6 , which includes a transgene downstream (3′) of the cytomegalovirus immediate/early promoter element.

8. A vector including the expression cassette of claim 6 .

9. An isolated host cell comprising the vector of claim 8 .

10. A DNA vaccine comprising the expression cassette or vector as claimed in claims 6 or 8 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2008
From: RYBICKI, EDWARD PETER; TANZER, FIONA LESLEY
To: SOUTH AFRICAN MEDICAL RESEARCH COUNCIL; UNIVERSITY OF CAPE TOWN
Reel/Frame 021238/0312 →
Priority Claims (1)
ZA 2005/09036 · Nov 8, 2005 · national
Continuity (1)
Related Publication 20090285852A1 · Nov 19, 2009